10 October 2021D. Parsons (Cambridge (MA) - USA)
In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.Retour ligne automatique
Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing. These manufacturing advances include scalable and Flexible manufacturing sites, Cell-free manufacturing process, Non-product-dedicated plants, Lower CapEx requirements and Smaller manufacturing footprint than traditional vaccines.